Metabolomics Global Market Report 2025

Metabolomics is the scientific study of small molecules known as metabolites, which are produced during metabolism within cells, tissues, or organisms. By analyzing and quantifying these metabolites, metabolomics provides valuable insights into biological processes, disease mechanisms, and metabolic pathways. This field plays a critical role in personalized medicine, drug discovery, and understanding the mechanisms of diseases such as cancer and diabetes.

The key products and services in the field of metabolomics encompass metabolomics instruments, metabolomics bioinformatics tools, and various services. Metabolomics instruments are specialized devices employed to comprehensively analyze low-molecular-weight compounds within biological samples. These instruments include separation techniques, detection methodologies, and metabolomics bioinformatics tools and services, which involve databases and bioinformatics tools. Metabolomics finds application in diverse medical indications such as cancer, cardiovascular disorders, neurological disorders, inborn errors of metabolism, and others. These applications are utilized for purposes such as biomarker discovery, drug discovery, toxicology testing, nutrigenomics, functional genomics, personalized medicine, and more.

The metabolomics market research report is one of a series of new reports from The Business Research Company that provides metabolomics market statistics, including metabolomics industry global market size, regional shares, competitors with a metabolomics market share, detailed metabolomics market segments, market trends and opportunities, and any further data you may need to thrive in the metabolomics industry. This metabolomics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The metabolomics market size has grown rapidly in recent years. It will grow from $3.62 billion in 2024 to $4.18 billion in 2025 at a compound annual growth rate (CAGR) of 15.4%. The growth in the historic period can be attributed to advancements in healthcare, drug discovery and development, disease biomarker identification, academic and research institutions, nutrition and food science.

The metabolomics market size is expected to see rapid growth in the next few years. It will grow to $7.99 billion in 2029 at a compound annual growth rate (CAGR) of 17.6%. The growth in the forecast period can be attributed to personalized healthcare, drug safety and efficacy, microbiome and gut health, environmental and agricultural applications, regenerative medicine. Major trends in the forecast period include integration with other omics, targeted metabolomics, single-cell metabolomics, data analytics and ai, point-of-care testing.

The increasing incidence of cancer is a primary driver of growth within the metabolomics market. Metabolomics, which scrutinizes potential biomarkers to assess cancer drug responsiveness, plays a vital role in early cancer diagnosis. For instance, in 2023, according to the American Cancer Society, a US-based professional organization, 1,958,310 new cancer cases and 609,820 cancer deaths are projected to occur in the United States, marking an increase from the previous year. Metabolomics methodologies, including nuclear magnetic resonance (NMR) and mass spectrometry (MS) techniques, are pivotal in studying cancer. Companies like Metabolon Inc. and Bruker Corp. have integrated metabolomics to aid in early cancer detection and treatment.

The rising prevalence of chronic diseases is poised to drive the metabolomics market's growth in the foreseeable future. Chronic ailments persist for a year or longer, necessitating ongoing medical intervention and often hindering daily activities. Metabolomics plays a crucial role in uncovering the metabolic underpinnings of chronic diseases, identifying pertinent biomarkers, and pinpointing potential targets for alternative therapies. Its ability to directly connect with an organism's phenotype makes it an invaluable tool in disease and health research. As highlighted in a March 2022 report by the Australian Bureau of Statistics, nearly three-quarters of Australians (78.6%) reported at least one long-term health issue, with almost half of the population (46.6% or 11.6 million individuals) affected by chronic conditions. Hence, the increasing prevalence of chronic diseases is a driving force behind the expansion of the metabolomics market.

The integration of machine learning is increasingly popular within the metabolomics field, significantly enhancing the efficiency of interpreting data obtained from metabolomics techniques. Machine learning-powered technologies automate complex and risky processes, streamline tasks, and offer swift, error-free services. Industry companies are favoring machine learning techniques for metabolism analysis, solving problems, and executing tasks. Various machine learning algorithms aid in metabolism data analysis and modeling metabolic pathways. Companies like Bio-Rad Laboratories, Metabolon Inc., among others, are leveraging machine learning algorithms to enhance understanding and prediction in metabolomics research. For example, MeltDB 2.0, a machine learning software utilized for metabolomics experiment data analysis and integration, provides robust research support, storing experimental datasets, and comprehensive analysis and visualization features to represent large and complex data effectively.

Major companies operating in the metabolomics market are focusing on introducing Integrated Bioinformatics Platforms to enhance the interpretation of complex metabolomic data, supporting advancements in personalized medicine, biomarker discovery, and disease understanding. An Integrated Bioinformatics Platform is a comprehensive software solution that combines various bioinformatics tools and databases, facilitating the analysis and interpretation of biological data. Researchers can map metabolomics data against precise biochemical pathway maps, helping to uncover biological processes and disease mechanisms. For instance, in February 2024, Metabolon, Inc., a US-based company, launched its bioinformatics platform. The "Biomarker Lenses" feature in the Integrated Bioinformatics Platform allows users to apply advanced analytical filters, focusing on metabolites linked to specific pathways or diseases, enabling targeted exploration of metabolomic data. The platform also includes tools for conducting statistical analyses like T-tests and ANOVAs, allowing researchers to build and compare statistical models, manage metadata, and visualize results effectively.

In October 2022, Clinical Microbiomics, a Denmark-based microbiome research company, acquired MS-Omics, a Denmark-based metabolomics company, for an undisclosed sum. This acquisition bolstered Clinical Microbiomics' portfolio by adding specialized metabolic profiling offerings. The addition of MS-Omics' capabilities is set to advance Clinical Microbiomics' systems biology platform, benefiting researchers globally.

Major companies operating in the metabolomics market include Human Metabolome Technologies Inc., Metabolon Inc., Bio-Rad Laboratories Inc., Bruker Corporation, Agilent Technologies Inc., Thermo Fisher Scientific Inc., Waters Corporation, Biocrates Life Sciences AG, Shimadzu Corporation, Danaher Corporation, Kore Technologies Ltd., Dani Instruments SpA, Perkinelmer Inc., Evans Analytical Group LLC, LECO Corporation, Phenomenome Discoveries Inc., AB Sciex, BG Medicine Inc., Biomark Diagnostics Inc., Chenomx Inc., Creative Proteomics, Evotec A.G, Merck kgaA, Southern Research Company Inc., Alcami Corporation, Charles River Laboratories International Inc., Eremid Genomic Services LLC, Metabowerke GmbH, Metabolomic Diagnostics, Phenomenex Inc.

North America was the largest region in the metabolomics market in 2024. Western Europe was the second largest region in the metabolomics market. The regions covered in the metabolomics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the metabolomics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada

The metabolomics market includes revenue earned by liquid chromatography, gas chromatography, capillary electrophoresis, mass spectrometry, and nuclear magnetic resonance spectroscopy. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Metabolomics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on metabolomics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for metabolomics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The metabolomics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Product And Service: Metabolomics Instruments; Metabolomics Bioinformatics Tools And Services
• 2) By Indication: Cancer; Cardiovascular Disorders; Neurological Disorders; Inborn Errors of Metabolism; Other Indications
• 3) By Application: Biomarker Discovery; Drug Discovery; Toxicology Testing; Nutrigenomics; Functional Genomics; Personalized Medicine; Other Applications
• Subsegments:
• 1) By Metabolomics Instruments: Chromatography Instruments (Gas Chromatography, Liquid Chromatography); Mass Spectrometry Instruments (LC-MS, GC-MS); NMR Instruments (Nuclear Magnetic Resonance); Others (Spectroscopy Instruments, Microarrays)
• 2) By Metabolomics Bioinformatics Tools And Services: Software Tools (Data Analysis, Statistical Tools, Modeling Tools); Database Services (Metabolomic Databases); Consulting Services (Data Interpretation, Analytical Support); Training And Support Services
• Companies Mentioned: Human Metabolome Technologies Inc.; Metabolon Inc.; Bio-Rad Laboratories Inc.; Bruker Corporation; Agilent Technologies Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.